Amphastar Pharmaceuticals, Inc. (AMPH)

Over the past six months, Amphastar Pharmaceuticals' stock has trended upwards, but over the past year, the stock has experienced a decrease. Key events impacting the stock price include Q1 2025 financial results where BAQSIMI and Primatene MIST sales increased while Glucagon and Epinephrine sales declined, a domestic production expansion plan, an exclusive licensing agreement with Nanjing Anji Biotechnology Co., Ltd., Q3 2025 earnings surpassing expectations, FDA approval for Teriparatide Injection, insider selling, and a new license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd.

The provided information does not explicitly detail the demand seasonality for Amphastar Pharmaceuticals, Inc.'s products and services.

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, markets, and sells technically challenging generic and proprietary injectable, inhalation, and intranasal products. The company's product portfolio includes BAQSIMI, Primatene MIST, Glucagon for Injection Emergency Kit, enoxaparin, naloxone, Cortrosyn, Amphadase, epinephrine injection, lidocaine jelly and topical solution, phytonadione injection, and insulin active pharmaceutical ingredients. Its products are used in hospital or urgent care settings and are distributed through group purchasing organizations and drug wholesalers.

Amphastar Pharmaceuticals, Inc. has a global presence with manufacturing facilities in the United States, China, and France. All finished products are produced domestically in the United States. Its market reach extends across the United States, Asia, and Europe, with the majority of its revenue generated from the U.S. market. The company's headquarters are in Rancho Cucamonga, California.

Amphastar Pharmaceuticals emphasizes its commitment to high quality and operates cGMP compliant facilities. The company faced criticism in the past for price increases of naloxone and an FDA rejection of an intranasal naloxone delivery device. However, Amphastar won a patent infringement lawsuit in March 2018. The company's expansion of domestic manufacturing capacity in July 2025 was highlighted as a commitment to the U.S. healthcare system and patients.

Amphastar Pharmaceuticals, Inc. has significant institutional ownership, with major holders including BlackRock, Inc., Vanguard Group Inc, and State Street Corp. Yong Feng Zhang, the co-founder and CEO, holds a substantial number of shares. Insiders collectively hold a significant portion of the company's stock, while retail investors hold approximately 33.28%.